White Pine Capital’s Myriad Genetics MYGN Stock Holding History

White Pine Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,025	Closed	-$344K	–	246
2017 Q4	$344K	Buy	10,025 +40	+0.4%	+$1.35K	0.13%	170
2017 Q3	$361	Sell	9,985 -10,465	-51%	-$298K	﹤0.01%	164
2017 Q2	$528K	Sell	20,450 -895	-4%	-$19K	0.21%	140
2017 Q1	$410K	Sell	21,345 -1,150	-5%	-$20.4K	0.17%	151
2016 Q4	$375K	Buy	22,495 +5,175	+30%	+$93.6K	0.16%	152
2016 Q3	$356K	Sell	17,320 -2,980	-15%	-$75.6K	0.15%	164
2016 Q2	$621K	Sell	20,300 -260	-1%	-$9.03K	0.26%	113
2016 Q1	$770K	Buy	20,560 +9,485	+86%	+$357K	0.33%	88
2015 Q4	$478K	Sell	11,075 -250	-2%	-$10.6K	0.21%	143
2015 Q3	$424K	Sell	11,325 -1,000	-8%	-$35.5K	0.2%	148
2015 Q2	$419K	Sell	12,325 -7,975	-39%	-$271K	0.18%	155
2015 Q1	$719K	Buy	+20,300	New	+$727K	0.29%	106

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

White Pine Capital's MYGN Position: Q1 2018 in Review

White Pine Capital sold out of Myriad Genetics (MYGN) in Q1 2018, closing a stake of 10,025 shares — an estimated $344K sold.

White Pine Capital first reported a position in MYGN in Q1 2015 and held it in 12 quarters. The position peaked at $770K in Q1 2016. 260 funds tracked by Wall St. Rank hold MYGN as of Q1 2018.

White Pine Capital reported no remaining Myriad Genetics position as of Q1 2018 after selling out during the quarter.
White Pine Capital sold 10,025 Myriad Genetics shares in Q1 2018, an estimated $344K.
White Pine Capital first reported a position in Myriad Genetics in Q1 2015 and held it in 12 quarters.
White Pine Capital's Myriad Genetics position peaked at $770K in Q1 2016.
260 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2018.

Based on White Pine Capital's 13F filing for Q1 2018, filed 14 May 2018.